FanMail, here are my two cents to your questio
Post# of 36537
here are my two cents to your questions. We for sure do not know what is really going on behind closed doors and why there is ZERO communication between the company and the public/us shareholders, that is surely true.
But I am definitely sure that there is a "Complete Vaccine" in development. Again, we do not know in what stage of the development it is, whether the clinical trials are already started, or it is still waiting FDA's approval of the IND application, but there DEFINITELY IS A "Complete Vaccine" candidate.
How do I know, you may rightfully ask!? Well, a Joint Equity group from China paid a total of 3 Million USD for what GNBT was able to show them in regards to pre-clinical test results. As Joe stated on here several times "Nobody pays $3 Million for nothing!" . So they have seen the lab test results, and they are convinced that these results are good, which is why they signed contracts with GNBT and started that Joint Equity Group with them, and paid the up front amounts.
Same way for Bintai Kinden. They signed contracts, and have put money aside ready to pay for all expenses that (will) occur during the US clinical trials, and that based on proof of the development work and laboratory testing that GNBT/NGIO have showed them.
So, you may not believe it, but there are cooperation partners that have signed contracts and paid (or put aside) money to fulfill their part of the negotiated and agreed upon deal with GNBT/NGIO.
Joe and his management team have always been very communicative in regards to PRs, conference calls and interviews with all sorts of Youtube channels, and right now there is utter silence on all these channels. Since this is the case, there must be a good reason as to why that is, and, of course, a negative thinking person can always assume that "the sky is falling onto his head", but more realistically it might as well be a much more simple explanation as an "SEC review". Or more politically, that maybe even the FDA is trying to hinder them to move forward with their vaccine development, just because they do not want to have a competitive other vaccine in the race, which might cause them to not get their millions of mRNA vaccine doses administered, because everyone wants that alternative vaccine.